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1. Introduction 
Since the discovery of the enkephalins [ 11, an 
extensive literature has been concerned with the rela- 
tionship between the chemical modifications of the 
peptidic structure and the classical parameters of a 
morphinomimetic activity [2-61. Among these syn- 
thetized analogs, it is noteworthy that (Pro)’ analogs 
are the most active compounds, especially when the 
second amino acid is also replaced by either D-Ala or 
D-Met [3,4]; these last substitutions strongly decrease 
the metabolic deactivation induced by various pep- 
tidases [7,8]. However, the exceptional nature of 
proline, that is an amino acid in which the amine func- 
tion is intracyclic, could possibly explain this high 
morphinomimetic activity. For these reasons, we 
were interested by the synthesis of an analog where 
the proline cycle is opened and for which the a-amino 
acid character is conserved: such an amino acid cor- 
responds to norvaline (N-Val). Here we report the 
synthesis of two related pentapeptides, (D-Ala*, 
N-Val’)-enkephalinamide and (D-Met*, N-Val’)- 
enkephalinamide and their pharmacological activity 
on the opiate and the enkephalin receptors. 
2. Materials and methods 
2.1. Chemical synthesis 
The enkephalin analogs were prepared as in [ 31. 
The degree of purity was evaluated on thin-layer 
chromatography or by high-pressure liquid chromato- 
graphy using a liquid chromatograph Waters ALC-204. 
The column 01 Bondapak Cl 8/Corasil, inverse phase) 
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was eluted with CH30H-H20 (1: 1). The enkephalin 
analogs were detected by their A*+,. 
2.2. Binding measurements 
Binding studies with [3H]etorphine were performed 
on a rat brain homogenate. Male Sprague-Dawley Rats 
(180-200 g) were killed by decapitation and the 
brain removed on ice. The cerebral tissue (minus 
cerebellum) was then homogenized with a Teflon- 
glass homogenizer (V = 1500 rev./min; 5 strokes) in 
110 vol. 0.05 M Tris-HCl buffer (pH 7.4). The crude 
homogenate (800 ~1) was incubated for 20 min at 
37°C in the presence of lOO/.d [3H]etorphlne (1 nM) 
and 100 ~1 unlabelled effector. Non-specific binding 
was determined with 1 PM Levorphanol. The reaction 
was stopped by the addition of 5 ml cold Tris-buffer 
and the resulting suspension was filtered under pres- 
surk on glass fiber filter Whatman GF/B. The filters 
were washed twice with 5 ml Tris-buffer, dried at 
12O’C for 15 min then counted in a Beckman scintil- 
lation counter using a scintillation mixture with 40% 
efficiency. 
For (D-Ala)2-Leu-[3H]enkephalinamide binding, a 
washed homogenate from mouse brain was used. Male 
Swiss mice (18-20 g) were killed and the homogenate 
prepared as before with the following modification: 
the homogenate was centrifuged at 49 000 X g for 
10 min and the resulting pellet was homogenized in 
10 ml Tris-buffer. After centrifugation (49 000 X g; 
10 min) the pellet was resuspended in sufficient 
Tris-buffer to obtain 1 mg protein/ml final cont. 
The binding assay was performed as previously 
described using 3.5 nM (D-Ala)2-Leu5-[3H]enkepha- 
linamide. Non-specific binding was measured in the 
Elsevier/North-Holland Biomedical Press 
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presence of 1 ,uM un~belled ligand. Bound ligand 
was separated from free ligand and counted. 
TheICse values were calculated by linear egression 
from log-probit plots and each value represents he 
mean ? SEM obtained in 3-4 separate xperiments, 
2.3. B~~l~~~a~ activity on ~~~a~ed organs 
Isolated ilea from guinea-pigs were placed in organ 
baths containing Krebs solution and then stimulated 
by field stimulation (0.1 Hz, 0.1 ms, maximal voltage). 
The longitudinal contractions were recorded iso- 
metrically. 
The agonist potency (inhibitory effect) of morphine 
and enkephalin analogs were tested by cumulative 
dose-response curves as in [9]. 
Isolated vas deferentia from mice were prepared 
and used as above and in [IO]. 
2.4. Drugs 
Morphine was a gift Francopia, Paris; [3H]etorphine 
(35.4 Ci/nmol) and (D-Ala)2-tyrosyl-3,5-[3H]enke- 
phalin (5L-leucine amide) (39.3 Ci/nmol) were 
purchased from the Radiochemical Center, Amersham. 
3. Results and discussion 
The data of table 1 and 2 clearly show that for the 
opiate receptor (N-Val)’ analogsare always more affme 
or active than the (Pro)’ analogs. It should be noted 
that the most important differences are observed 
when the (D-Ala)2 derivatives are compared. Similar 
conclusions can be established for the enkephalin 
receptor from the data reported in table 1 and 2. For 
the (D-Ala)* analogs, the replacement ofPro by N-Val 
leads to a compound which is >lO-times more active 
than the (Pro)” analog on both assays. The general 
conclusion that can be drawn from these findings is 
that the integrity of Pro cycle is not necessary for 
the in vitro activity. In fact (N-Val)s analogs are 
generally more active than the corresponding (Pro)5 
derivatives. 
We have determ~ed the influence of such amino 
acid replacement on the binding of analogs to the two 
types of receptors [Ill, that have been best charac- 
terized, i.e., opiate receptors (or or receptors) and 
enkephalin receptors (or 6 receptors). [3H]Opiates 
have been reported to label opiate receptors which 
Table 1 
Affinity of morphine and enkephalin analogs for [ 3H]etorphine sites and 
(D-Ala’, Leu “)-f 3 H] enkephalmamide sites 
Compound [ ‘H]Etorphine (D-Ala’, Leus)-[3H]~nkeph~~amide 
IC,, cm@ IC,, tnM) 
Morphine 170 * 10 120 t 19 
(D-Met’, Pros)-Enkephahnamide 82 f 23 21* 1 
(D-Met’, N-V~‘)-E~eph~n~ide 60 * 22 18t 2 
(D-Ala’, ~05)-E~ephal~amide 340 * 90 90 r 14 
(D-Ala2, N-V~‘)-Enkeph~amide 58 I 6 92 2 
Table 2 
Agonist potency of morphine and enkephalin analogs on gull-pig ileum and 
mouse vas deferens 
~ ~-~ 
Compound Guinea-pig ileum Mouse vas deferens 
IC,, (nM) IC,, (nM) 
Morphine 80 t 12 417 * 75 
(D-Met’, ~o$)-Enkeph~~amide 14 2 1 21* 2 
(D-Met’, N-V~5)-E~eph~namide lit 1 172 4 
(D-Ala*, Pros)-Enkephalinamide so* 1 114 f 3.5 
(D-Ala’, N-Val’)-Enkephalinamide 25i 1 7* 2 
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are the majority of receptors present in guinea-pig 
ileum [l l] and [3H]peptides have been shown to 
characterize enkephalin receptors, mainly found in 
mouse vas deferens [ 111. We have shown that there 
exists a strong correlation between the affinity for 
[3H]etorphine binding site in rat brain and the 
inhibitory activity determined in guinea-pig ileum 
[12]. Similarly, the affinity for (D-Ala’, Leu’)- 
[3H]enkephalinamide binding sites in mouse brain 
correlates with the depressant activity measured in 
mouse vas deferens [ 121. We could therefore deter- 
mine the influence of pro and N-Val on the peptide 
affinity for the two types of receptors. 
(D-Met)’ compounds have been shown equiactive 
on opiate and enkephalin receptors [5-121 and 
replacement of Pro by N-Val does not modify this 
pharmacological profile nor affect the corresponding 
activity. However, very different results are obtained 
with (D-Ala)? analogs: whereas (D-Ala’, Pro’)enke- 
phalinamide is somewhat more active on opiate 
receptors than on enkephalin receptors, (D-Ala’, 
N-Val’)enkephalinamide is considerably more active 
on both kind of receptors, especially on enkephalin 
receptors. Evidently replacing Pro with its chemical 
isomer N-Val alters the discrimination of enkephalins 
for the two types of opiate receptors. 
In conclusion, (D-Met’, N-ValS)enkephalinamide 
and particularly (D-Ala’, N-Val’)enkephalinamide 
are two potent agonists of opiate and enkephalin 
receptors, more active than (D-Met’, Pro’)-enke- 
phalinamide itself. 
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